Xcout IntelOS Therapies Incorporated competitors & alternatives
The 12 closest competitors and alternatives to OS Therapies Incorporated among biotechnology companies — ranked by similarity to what OS Therapies Incorporated actually does, not by market-cap band.
Subscribe to see OS Therapies Incorporated’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OS Therapies Incorporated at a glance
OS Therapies Incorporated is a biotechnology company headquartered in Grasonville, United States. It is publicly listed (OSTX) with a market capitalisation of $68.1M. Xcout tracks 39 named people at OS Therapies Incorporated, including Borys Shor (President & CEO Manhattan BioSciences).
OS Therapies Incorporated leadership
- Borys ShorPresident & CEO Manhattan BioSciences
- Paul A. RomnessChief Executive Officer
- Paul RomnessChair Chief Executive Officer President
- Christopher AcevedoChief Financial Officer
- Chris AcevedoCFO
- Christopher P. AcevedoChief Financial Officer
33 more named people on record for OS Therapies Incorporated, with roles, board committees and tenure — see the full roster →
Top 12 OS Therapies Incorporated competitors
Ranked by semantic similarity — how close each company is to OS Therapies Incorporated by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Biotech
OSE Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for immune activation and regulation in immuno-oncology and immuno-inflammation. The company utilizes proprietary research platforms and a portfolio of clinical-stage assets to provide therapeutic options for patients.
Biotech
Oxford BioTherapeutics is a clinical-stage oncology company focused on developing first-in-class cancer therapeutics with a proprietary pipeline. The company operates from locations in Oxford, United Kingdom, as well as San Jose, California, and Morristown, New Jersey, in the United States.
Biotech
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
Life Sciences
OncXerna Therapeutics is a clinical-stage precision-oncology biotechnology company that develops RNA-based biomarkers and targeted cancer therapies. Its work is intended to help identify cancer patients most likely to benefit from particular treatments and support oncologists and pharmaceutical partners in treatment selection.
Similar biotechnology company
VelosBio Inc. is a clinical-stage biopharmaceutical company based in California, United States, focused on developing novel antibody-drug conjugates to transform cancer treatment for patients.
Similar biotechnology company
OncoC4, Inc. is a privately held, late clinical-stage biopharmaceutical company based in Rockville, Maryland, focused on discovering and developing novel medicines for cancer treatment.
Similar biotechnology company
OneChain Immunotherapeutics is a biotechnology company based in Barcelona focused on the development of CAR-T cell therapies and in vivo platforms for cancer immunotherapy.
Biotech
TwoStep Therapeutics, Inc. is a biotechnology company developing a tumor-targeting platform built around a polyspecific integrin-binding peptide ("PIP") designed to deliver diverse payloads for solid tumors. Led by CEO and Co-Founder Tlyn Miller, the company focuses on expanding the reach of targeted cancer therapies.
Biotech
Deka Biosciences, Inc. is an early-stage biotechnology holding company located in Germantown, Maryland, focused on developing and delivering life-changing medicines for cancer patients.
Similar biotechnology company
Theradaptive, Inc. is a clinical-stage biotechnology company headquartered in Frederick, Maryland, that engineers proteins to bind materials for targeted tissue therapeutics, tissue regeneration, and implantable delivery devices.
Similar biotechnology company
OncoRock Therapeutics Inc. is a corporation located in Little Rock, Arkansas. The company operates in the life sciences sector, focusing on the research and development of oncology therapeutics.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of OS Therapies Incorporated and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for OS Therapies Incorporatedand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →